WallStreetZenWallStreetZen

NASDAQ: PRLD
Prelude Therapeutics Inc Stock Ownership - Who owns Prelude Therapeutics?

OverviewForecastEarningsDividendOwnership

Insider buying vs selling

Have Prelude Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Jane HuangPresident CMO2024-04-043,347$4.74
$15.86kSell
Jane HuangPresident CMO2024-01-043,844$3.77
$14.49kSell
Jane HuangPresident CMO2023-07-043,242$4.65
$15.08kSell
Krishna VaddiCEO2023-05-25900$5.31
$4.78kBuy
Bryant David LimChief Legal Officer Corp Sec.2023-05-242,400$5.39
$12.94kBuy
Krishna VaddiCEO2023-05-241,000$5.01
$5.01kBuy
Krishna VaddiCEO2023-05-2311,856$5.63
$66.75kBuy
Laurent ChardonnetChief Financial Officer2023-05-235,000$5.50
$27.50kBuy
Orbimed Advisors LLCDirector2023-05-22869,565$5.75
$5.00MBuy
David P. BonitaDirector2023-05-22869,565$5.75
$5.00MBuy

1 of 1

PRLD insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when PRLD insiders and whales buy or sell their stock.

PRLD Shareholders

What type of owners hold Prelude Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Orbimed Advisors LLC19.86%10,909,256$53.56MInstitution
Baker Bros Advisors LP18.43%10,123,824$49.71MInstitution
David P. Bonita17.80%9,776,491$48.00MInsider
Orbimed Advisors LLC17.80%9,776,491$48.00MInsider
Baker Bros Advisors LP16.85%9,252,951$45.43MInsider
Deerfield Management Company LP Series C7.53%4,133,000$20.29MInstitution
Boxer Capital LLC4.68%2,568,287$12.61MInstitution
Krishna Vaddi2.93%1,611,595$7.91MInsider
Blackrock Inc1.99%1,095,589$5.38MInstitution
Price T Rowe Associates Inc1.90%1,042,737$5.12MInstitution

1 of 3

PRLD vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
PRLD52.43%47.57%Net BuyingNet Selling
ALDX59.63%34.19%Net SellingNet Buying
ACRV46.35%53.65%Net BuyingNet Buying
ADVM72.30%27.70%Net BuyingNet Buying
GTHX24.18%47.08%Net SellingNet Selling
View Top Biotech Stocks

Prelude Therapeutics Stock Ownership FAQ

Who owns Prelude Therapeutics?

Prelude Therapeutics (NASDAQ: PRLD) is owned by 63.23% institutional shareholders, 57.36% Prelude Therapeutics insiders, and 0.00% retail investors. David P. Bonita is the largest individual Prelude Therapeutics shareholder, owning 9.78M shares representing 17.80% of the company. David P. Bonita's Prelude Therapeutics shares are currently valued at $40.87M.

If you're new to stock investing, here's how to buy Prelude Therapeutics stock.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.